MIBG for Refractory Neuroblastoma and Pheochromocytoma

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a best available therapy/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Masonic Cancer Center, University of Minnesota
• Treatments: 3-Iodobenzylguanidine; Iodine; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Diagnosis:

• Relapsed/refractory neuroblastoma with original diagnosis based on tumor histopathology or elevated urine catecholamines with typical neuroblastoma cells in the bone marrow

• Metastatic pheochromocytoma

• Age >1 year and able to cooperate with radiation safety restrictions during therapy period

• Karnofsky or Lansky performance status of ≥ 50%

• Life expectancy: ≥ at least 8 weeks

• Disease status: Failure to respond to standard therapy or development of progressive disease at any time.

• Disease must be evaluable by MIBG scan. A positive MIBG scan must be present within 8 weeks prior to study entry and subsequent to any intervening therapy. If the patient has only one MIBG positive lesion and that lesion was radiated, a biopsy must be done at least 4 weeks after radiation was completed and must show viable neuroblastoma.

• Stem Cells: Patients must have a hematopoietic stem cell product available for reinfusion after MIBG treatment at doses of > 12 mCi/kg.

• Have acceptable organ function as defined below within 7 days of enrollment:

• Bone Marrow: ANC ≥750 X 109 /L and platelets ≥50,000 X 109 /L without transfusion if stem cells are not available (any ANC or platelet allowed if stem cells available)

• Renal: Creatinine ≤3x upper limit of normal

• Hepatic: Bilirubin ≤2x upper limit of normal; AST/ALT ≤10x upper limit of normal

• Cardiac: Ejection fraction ≥45% on echocardiogram

• Pulmonary: normal lung function as manifested by no dyspnea and/or oxygen saturation ≥ 88% on room air.

• Prior Therapy: Patients must have recovered from all acute toxicities (defined as CTCAE 4.0 ≤ grade 1) associated with any prior therapy, and:

• Myelosuppressive chemotherapy: At least 2 weeks should have elapsed since any chemotherapy causing myelosuppression

• Biologic (anti-neoplastic agent): At least 7 days should have elapsed since the completion of therapy with a biologic agent.

• Monoclonal antibodies: At least 3 half-lives should have elapsed since therapy with a monoclonal antibody

• Radiation therapy: Three-months should have elapsed in the case of completing radiation to any of the following fields: craniospinal, total abdominal, whole lung, total body irradiation). For all other sites of radiation, at least 2 weeks should have relapsed.

• Cytokine therapy (e.g. G-CSF, GM-CSF, IL-6, IL-2): must be discontinued a minimum of 24 hours prior to MIBG therapy.

• Voluntary written informed consent

Exclusion Criteria:

• Patients with disease of any major organ system that would compromise their ability to withstand therapy.

• Because of the teratogenic potential of the study medication, no patients who are pregnant or lactating will be allowed. Patients of childbearing potential must practice an effective method of birth control while participating on this study, to avoid possible damage to the fetus.

• Known allergy to any of the agents or their ingredients used in this study.

• Patients who are on hemodialysis

• Patients with untreated positive blood cultures or progressive infections as assessed by radiographic studies